CoChat

No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial

Hegedüs, Laszlo, Sherman, Steven I., Tuttle, R. Michael, von Scholten, Bernt J., Rasmussen, Søren, Karsbøl, Julie D., Daniels, Gilbert H., for the LEADER Publication Committee on behalf of the LEADER Trial Investigators · 2018 · Diabetes Care

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To describe the changes in serum levels of calcitonin in liraglutide- and placebo-treated patients in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER) trial over a 3.5–5-year period. RESEARCH DESIGN AND METHODS: Patients (n = 9,340) with type 2 diabetes and high risk for cardiovascular events were randomized 1:1 to liraglutide or placebo. We analyzed calcitonin levels, thyroid and C-cell adverse events, and neoplasms. RESULTS: At 36 months, patients randomized to liraglutide versus placebo showed no evidence of increase in calcitonin concentrations in male (estimated treatment ratio [ETR] 1.03 [95% CI 1.00, 1.06]; P = 0.068) and female (ETR 1.00 [95% CI 0.97, 1.02]; P = 0.671) subgroups. There were no episodes of C-cell hyperplasia or medullary thyroid carcinoma in liraglutide-treated patients. CONCLUSIONS: There was no evidence of a difference in calcitonin concentrations between the liraglutide and placebo groups, and no C-cell malignancies occurred in the liraglutide group.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc17-1956

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 67

Metadata

Authors
Hegedüs, L., Sherman, S. I., Tuttle, R. M., von Scholten, B. J., Rasmussen, S., Karsbøl, J. D., Daniels, G. H., & for the LEADER Publication Committee on behalf of the LEADER Trial Investigators
Affiliations
  • Department of Endocrinology, Odense University Hospital, Odense, Denmark
  • The University of Texas MD Anderson Cancer Center (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Novo Nordisk A/S, Søborg, Denmark
  • Novo Nordisk (Denmark) (DK)
  • Harvard University (US)
Venue
Diabetes Care
Published
2017-12-26
Volume
41
Issue
3
Pages
620-622
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2778933123
Cited by
67
References
10
Citations by year
2026: 9 · 2025: 10 · 2024: 12 · 2023: 10 · 2022: 6 · 2021: 2 · 2020: 9 · 2019: 6 · 2018: 3
FWCI
3.89
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
liraglutide, calcitonin, C-cell hyperplasia, medullary thyroid carcinoma, type 2 diabetes, GLP-1 receptor agonists, thyroid cancer risk, long-term safety, cardiovascular outcomes, LEADER trial
MeSH terms
Liraglutide, Calcitonin, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Humans, Hyperplasia, Hypoglycemic Agents, Male, Middle Aged, Neoplasms, Thyroid Neoplasms, Biomarkers, Tumor, Body Mass Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.